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Abstract Given the advantages of being stable in the ambient
environment, being permeable to the blood–brain and/or
blood–eye barriers and being convenient for administration,
naturopathic compounds have growingly become promising
therapeutic candidates for neural protection. Extracted from
one of the most common Chinese herbal medicines, tetrame-
thylpyrazine (TMP), also designated as ligustrazine, has been
suggested to be neuroprotective in the central nervous system
as well as the peripheral nerve network. Although the detailed
molecularmechanisms ofitsefficacy for neural protection are
understood limitedly, accumulating evidence suggests that
antioxidative stress, antagonism for calcium, and suppres-
sion of pro-inflammatory factors contribute significantly to
its neuroprotection. In animal studies, systemic administra-
tion of TMP (subcutaneous injection, 50 mg/kg) significant-
ly blocked neuronal degeneration in hippocampus as well as
the other vulnerable regions in brains of Sprague–Dawley
rats following kainate-induced prolonged seizures. Results
from us and others also demonstrated potent neuroprotective
efficacy of TMP for retinal cells and robust benefits for brain
in Alzheimer’s disease or other brain injury. These results
suggest a promising prospect for TMP to be used as a
treatment of specific neurodegenerative diseases. Given the
assessment of the distribution, metabolism, excretion, and
toxicity information that is already available on most
neuroprotective naturopathic compounds such as TMP,
preclinical data to justify bringing such therapeutic com-
pounds to clinical trials in humans is feasible.
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Introduction
Neuronal degeneration, i.e., neuronal cell death, underlies
the pathology and malfunction of many different neurolog-
ical diseases occurring in both animals and human beings.
Progressive and selective neuronal cell death in the central
nervous system (CNS) and/or the peripheral nerve network
has been profoundly implicated in the pathogenesis of
neurodegenerative disorders including Alzheimer’s disease
(AD), Parkinson’s disease, Huntington’sd i s e a s e ,L o u
Gehrig’s disease or amyotrophic lateral sclerosis, multiple
sclerosis, epilepsy, stroke, traumatic injury, age-related
macular degeneration, glaucoma, prion diseases, infections,
and so on [1, 2]. Evidence is rapidly accumulating to
suggest that selective neuronal cell death through necrosis
and/or apoptotic mechanisms contributes significantly to
the functional anomalies of specific neurologic disorders
[1]. Changes of genetic, epigenetic, metabolic, and envi-
ronmental factors might directly or indirectly cause (1)
massive DNA damage, (2) dysfunction of the ubiquitin-
proteasomal system, (3) disruption of the axonal transport
machinery, (4) abnormalities of mitochondrial structure and
function, (4) disturbance of intracellular ionic homeostasis
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reactive oxygen species (ROS) in the neuronal cells.
Accumulating intracellular stress subsequently results in
(1) loss of spines and synapses, (2) fragmentation of
neuronal processes and extended neuritic degeneration
leading to demyelination, (3) global neuronal cell death
leading to activation of signal transduction cascade for
programmed cell death, (4) anomalies of microvasculature,
and (5) provoked neuroinflammatory response leading to
destructive pathogenic changes (see several representative
reviews) [1–4]. Accordingly, the main aim of neural
protection in neurodegenerative disorders is to retard progres-
sion by blocking the mechanisms that lead to neuronal cell
death as well as associated neuroinflammatory events.
Considerable efforts have been made in recent decades to
discover new potential therapeuticcompoundsthatcan helpto
prevent the onset or to slow down the progression of such
diseases. Equal attempts are in progress to improve the
therapeutic efficacy of known medications through chemical
modification. Given the evident advantages of being stable in
the ambient environment, being permeable to the blood–brain
and/or blood–eye barriers, and being convenient for admin-
istration (Fig. 1), naturopathic compounds have increasingly
become suitable therapeutic candidates for neural protection
fromthesensorysystemincludingretinatothecentralnervous
system(brain).Table1 summarizes a group of selected herbal
extracts that have demonstrated significant neuroprotective
efficacy both in vivo and in vitro. Taking tetramethylpyrazine
(TMP) as an example, the neuroprotective efficacy and
related issues are discussed here.
Tetramethylpyrazine, an herbal extract showing
multiple protective effects on cells and benefits
on physiological function
As listed in Table 1, TMP, also designated as ligustrazine, is
an alkaloid extracted from the Chinese herbal medicine,
Ligusticum wallichii Franchat (chuanxiong)[ 5]. For
hundreds of years, chuanxiong has been used as a traditional
Chinese medicine for heart, kidney, and brain diseases [6, 7].
Experimental studies demonstrated that TMP treatments
significantly improved cardiac and cerebral blood flow and
elevated blood reperfusion as shown in the nail microcircula-
tion[8, 9]. In an ex vivo study, a semi-synthetic form of TMP
monomer induced a dose-dependent relaxation of human
pulmonary and bronchial arteries [10]. TMP also exhibited a
calcium antagonist role in vascular tissues [11]; functioned as
a ROS scavenger to deactivate cytotoxic ROS such as
superoxide anion (O2−), hydroxyl (OH−), and lipid peroxyl
(LOO−)f r e er a d i c a l s[ 12, 13]; and inhibited inflammatory
events in vivo possibly through modulating secretion of
specific cytokines and nitric oxide-related pathways [14–16].
About two decades ago, a study briefly reported that
TMP alleviated ischemic retinal degeneration in vivo [17].
Recently, a different group of researchers demonstrated that
systemic injection of TMP significantly protected retinal
photoreceptors from loss induced by N-methyl-N-nitrosourea
in rats [18]. Further, we demonstrated that TMP efficiently
enhanced in vitro survival of cultured rat retinal cells and
significantly attenuated cell damage in these cells exposed
to hydrogen peroxide [19].
Fig. 1 The conventional route
of most natural compounds from
herbs to target organs. In the
traditional Chinese medicine,
the herbal therapeutic
ingredients are extracted and
prepared as herbal tea or soup
with water through regular
cooking and taken orally. The
effective ingredients are
absorbed by the gastrointestinal
tract and successfully pass
through the blood–brain and/or
blood–eye barriers to reach the
targets, brain and/or retinas
(graphic clips were taken from
the Internet free sources)
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and attenuated neuronal cell death in neuronal cultures
following iron-mediated oxidative damage and glutamate-
mediated excitotoxicity [20–22]. Systemic administration of
TMP protected neuronal cells against ischemic or traumatic
brain or spinal cord injury and promoted functional recovery
in rodents and rabbits [23, 24]. Interestingly, systemic
administration of TMP also attenuated impairment of learning
and memory performance in rodents following D-galactose-
or ischemia-induced brain injury [25, 26]. The potential
therapeutic efficacy of TMP for AD is further supported by
our recent observations about significant improvement of
cognitive function as well as cerebral amyloid pathology in
t h ed e m e n t e dA l z h e i m e r ’s triple transgenic (3xTg-AD) mice
(Tan et al., unpublished observations). These findings suggest
that TMP has potent neuroprotective efficacy.
TMP protects neuronal degeneration in rat brain
against excitotoxicity—an experimental study
Systemic administration of the excitotoxin, kainic acid
(KA), a glutamate analog, causes prolonged seizures result-
ing in massive neuronal cell death in rat brain. KA-induced
neuronal degeneration is one of the most common animal
models for excitotoxic neuronal cell death, which is
apparently involved in the pathogenesis of multiple neuro-
degenerative disorders [27–29]. One-month old male
Sprague–Dawley rats were housed and treated according
to the National Institutes of Health guidelines for the care
and use of laboratory animals and a protocol approved by
the UCI Institutional Animal Care and Use Committee. One
hour after the onset of seizures following subcutaneous
(s.c.) injection of KA (10.5 mg/kg), rats received TMP
(50 mg/kg, s.c.) or an equal volume of vehicle. Untreated
animals, which received neither KA not TMP, were used as
blank controls. All the animals (N=6 each group) were
decapitated 24 h after TMP or vehicle injection under CO2
gas-induced deep anesthesia. The brain was rapidly
harvested, frozen, and cryosectioned in the coronal plane
at10µm.Adjacentsectionsfromeachbrainwerestainedwith
hematoxylin–eosin (H & E) and in situ cell death assay kit for
terminal deoxytransferase-mediated dUTP nick end labeling
(TUNEL; Roche, Indianapolis, IN, USA), respectively, as
described in our previous work [30, 31].
Systemic administration of KA resulted in a well-
described pattern of behavioral seizures including wet dog
shake at the beginning stage and progressed to tonic–clonic
activity [27]. Seizures typically occurred intermittently
during the first 6–8 h and yielded about 10% or less mortality.
As observed in this study, TMP treatments did not alter the
patternandtheseverityoftheseizures.Brainsectionsfromthe
animals that received “KA + vehicle” demonstrated robust
neuronal degeneration in KA-vulnerable regions in brain as
revealed by both H & E staining and TUNEL labeling
(Fig. 2a (f–j)) whereas the controls showed no eosinophilic
Table 1 List of selected naturopathic compounds that have demonstrated neuroprotective efficacy in both retina and brain
Name Natural sources (selected) Structural classification Selected studies
Baicalein Radix scutellariae Alkaloids C [49, 50]; R [51, 52]; B [53, 54]
Chlorogenic acid Eucommia or other plants Polyphenolics C [55]; R [56]; B [57, 58]
Curcumin Curcuma longa Alkaloids C [59, 60]; R [59, 61]; B [60, 62, 63]
Emodin Leguminosae seed Alkaloids C [64, 65]; R [66]; B [65, 67]
Fisetin Rhus cotinus bark Polyphenolics C [68, 69]; R [70]; B [71]
Kaempferol Euonymus alatus or Impatiens balsamina Flavonoids C [72, 73]; R [70, 74]; B [75]
Ligustrazine Ligusticum wallichii roots Alkaloids C [19]; R [76]; B [23, 77]
Morin The Moraceae family, e.g., mulberry Flavonoids C [78]; R [79]; B [80, 81]
Myricetin Myrica rubra Flavonoids C [78]; R [74]; B [82]
Naringenin Satureja obovata Flavonoids C [83]; R [84]; B [85]
Paeoniflorin Paeony roots Polyphenolics C [86]; R [87]; B [88–90]
Puerarin Pueraria lobata roots Alkaloids C [91, 92]; R [93, 94]; B [95, 96]
Pycnogenol Pinus maritime bark Flavonoids C [97]; R [98, 99]; B [100]
Quercetin Euonymus alatus Flavonoids C [101, 102]; R [84, 103]; B [104, 105].
Resveratrol Grapes Flavonoids C [106, 107]; R [108]; B [108–110]
Rutin Buckwheat Flavonoids C [111]; R [84]; B [104]
Wogonin Scutellaria baicalensis Flavonoids C [112, 113]; R [114]; B [115, 116]
C, in vitro studies conducted in cultured cells; R, in vivo studies showing retinal protection; B, in vivo studies demonstrating neuroprotective
efficacy in the brain
j ocul biol dis inform (2009) 2:137–144 139or TUNEL-positive damaged cells (Fig. 2a (a–e)). In
contrast, given 50 mg/kg TMP following the onset of
seizures, animals showed markedly fewer damaged cells in
the corresponding regions in the brain (Fig. 2a (k–o)).
Quantification of TUNEL-positive cells conducted as de-
scribed in our previous work [32, 33] revealed a statistically
significant difference between “KA + vehicle” and “KA +
TMP”, suggesting remarkable neuroprotective efficacy of
TMP in the CNS under excitotoxic attack.
In cultured neural cells, TMP treatments significantly
reduced the generation of lipid peroxidation products,
malondialdehyde, induced by hydrogen peroxide [19, 20].
These observations are also in agreement with increased
levels of glutathione in 3xTg-AD mouse brains following
TMP treatments (data not shown). In addition, the benefits of
TMP treatments preserved high levels of MAP2 and rattin,
two molecules that play important roles in cell growth and
function [19, 34, 35]. Taken together, TMP may target
Fig. 2 Systemic administration
of TMP attenuates neuronal
degeneration in rat brains
following kainate-induced
seizures. a Both hematoxylin–
eosin (H & E) and TUNEL
staining demonstrate massive
neuronal damage shown as pink
in H & E staining (f, g) and
green in TUNEL (h, i, and j)i n
both hippocampus (f, g, h, and i)
and piriform cortex (j) regions.
In contrast, the animals received
TMP only exhibited a few
sporadic eosinophilic (l) and
TUNEL-positive cells in the
corresponding regions (m, n,
and o). b Quantification of
TUNEL-positive cells according
to our previous methods reveals
a significant decrease in the
number of damaged neurons
in the hippocampal regions
with TMP treatment. Scale bar=
100 µm in b, d, e, g, i, j, l, n, and
o; and 400 µm in a, c, f, h, k,
and m
140 j ocul biol dis inform (2009) 2:137–144multiple cell signal transduction pathways to contribute to
the survival of neural cells and the normal function of the
nervous system.
How far is TMP from the next phase for clinical
applications?
As a naturopathic compound isolated from a Chinese herbal
medicine, TMP has been the subject of many pharmaco-
logical and toxicological studies. The solubility of purified
TMP in crystal form is relatively low in neutral aqueous
solution (~10 µg/ml) and dramatically increases in an acidic
environment (>40 mg/ml, pH <4), in which TMP is stable
and active [36]. Preclinical assessment of the distribution,
metabolism, excretion, and toxicity (ADMET) of TMP has
been performed in animals and in vitro for over 20 years
[37–41]. Pharmacokinetic studies demonstrated that TMP
was efficiently permeable to the blood–brain barrier in
multiple animal models [39, 40]. Toxicity assays revealed a
very low level of toxicity in animals with an oral LD50 of
about 1,910 mg/kg in rats and 1,436 mg/kg in mice [42, 43].
Of significance, practitioners of traditional Chinese medicine
have continued to use TMP as a treatment for inflammatory
or degenerative diseases, usually in combination with other
medications [6, 8, 44–46]. In this regard, both TMP tablets
and TMP–HCl injectable solution are prescription-available
for the treatment of cardiovascular diseases in China [47, 48].
Given the favorable ADMET outcomes on TMP in
animals, and the longstanding clinical use of TMP in China,
the path is set for preclinical data to justify clinical trials of
TMP in humans. This proof-of-concept proposal would
provide sufficient preclinical evidence to justify studying
TMP in patients with neurodegenerative disorders in a
double-blind placebo-controlled manner. Our understanding
of the molecular basis for TMP-mediated pharmacological
actions remains limited. Similarly, there are a lack of
well-designed preclinical studies of TMP efficacy for
neurological disorders. Such studies are critical prior to
studying TMP in humans.
Summary
In addition to TMP, there are groups of naturopathic
compounds that have been purified from related herbal
medicines and identified as efficient neuroprotective ingre-
dients as mentioned. Resembling TMP, many of these
compounds have demonstrated remarkable neuroprotective
efficacy in experimental studies conducted in cell cultures
and/or live animals. Some of them are also used in clinics
as treatment for specific neurological disorders. Therefore,
once further studies are warranted to decipher the molecular
basis of related pharmacological efficacy, many of such
naturopathic molecules would move to clinical assessments
for neural protection in humans.
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